The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · cited 2×
“Combination with targeted agents As tumorigenesis has been shown to be a multifaceted process involving a variety of signalling targets, further improvement may be achieved by combining different biological agents (Wade et al. 2013).”
BackgroundCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070 · cited 1×
“This is pertinent in the light of the limitations of standard cancer treatment, such as radiotherapy and chemotherapy, which remains a significant obstacle due to the development of drugresistant tumours (Hu et al. 2010; Al-Lazikani et al. 2012).”
BackgroundShimizu, T., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Smith, L. S., Gunn, S., Smetzer, L., Mays, T. A., Kaiser, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2381 · Cited by 431
PTEN function: the long and the short of it
Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.006 · Cited by 309 · cited 2×
“Subsequently, activated Akt transduces antiapoptotic signals by phosphorylating and inactivating key proteins involved in cell proliferation and survival, such as BAD, caspase-9, and forkhead (FoxO1/3a) transcription factors (Hopkins et al. 2014).”
BackgroundGandhi, L., Bahleda, R., Tolaney, S. M., Kwak, E. L., Cleary, J. M., Pandya, S. S., Hollebecque, A., Abbas, R., Ananthakrishnan, R., Berkenblit, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2787 · Cited by 198
Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1777 · Cited by 152
Cited by
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Z., Tao, T., Li, H., & Zhu, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00396-1 · Cited by 927
Dekhne, A. S., Ning, C., Nayeen, M. J., Shah, K., Kalpage, H., Frühauf, J., Wallace-Povirk, A., O’Connor, C., Hou, Z., Kim, S., et al. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117937 · Cited by 40
“Both elevated AICA ribonucleotide (via activation of AMPK) (Racanelli et al., 2009; Rothbart et al., 2010) and decreased purines (Hoxhaj et al., 2017) can suppress the prosurvival mTOR pathway (Lim et al., 2015).”
Metadata
- Authors
- Lim, H. J., Crowe, P., & Yang, J.-L.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2014-08-22
- Volume
- 141
- Issue
- 4
- Pages
- 671-689
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2046178435
- Cited by
- 166
- References
- 8
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. https://app.cochat.ai/papers/10.1007/s00432-014-1803-3
- The paper
- Lim, H. J., Crowe, P., & Yang, J.-L. (2015). Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-014-1803-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.